The Luo Lab studies hypoxia-inducible factor (HIF)-dependent and independent epigenetic and metabolic alterations in development and tumorigenesis with a goal of identifying vulnerability to treat cancers. We utilize in vitro and in vivo models including genetic mouse models, patient-derived xenograft models, and organoid models in our studies. Currently, our research is supported by grants from NCI, CPRIT, and ACS.
Research Overview We are interested in the role of post-translational modifications in HIF transcriptional activity (Bao L, et al., Nucleic Acids Res 2018; Luo W et al., J Biol Chem 2010).
We are interested in studying interplay between HIF and epigenetic regulators as well as epigenetic regulation of development and cancer (Wang Y, et al., Cancer Res 2020; Chen Y, et al., JCI 2018).
We are interested in identification of HIF-dependent metabolic reprogramming in human cancers and possible metabolic therapy (Zhang B, Chen Y, et al. Cell Mol Life Sci 2021; Peng H et al. Oncogene 2020; Zhang B, Chen Y, et al., Cells 2022).
We are interested in epigenetic and metabolic regulation of development and tumorigenesis and their therapies (Luo M, et al., Sci Adv 2022; Zhang B, Peng H, et al., Cancer Res 2022; Wang Y et al., Cancer Res 2021).